Patent Infringement Case

Related by string. * patents . Patents . patented . patenting : patent infringement suit . patent infringement lawsuits . Patent Portfolio / infringements . Infringements . INFRINGEMENT : patent infringement lawsuit . constitutes copyright infringement liable . trademark infringement unfair / cases . CASE . Cases : visit www.rmclasslaw.com cases . Cold Case . P Case Shiller * *

Related by context. All words. (Click for frequent words.) 87 Patent Infringement Lawsuit 85 Patent Infringement Suit 85 Patent Lawsuit 85 Wins Patent Infringement 83 Patent Dispute 83 Patent Ruling 82 Files Patent Infringement 80 Patent Infringement 80 Patent Infringement Litigation 80 Patent Suit 80 Patent Infringement Action 79 Files Patent Infringement Suit 79 Patent Infringement Lawsuit Against 78 Patent Lawsuit Against 78 Settles Patent 78 Patent Suit Against 77 Patent Infringement Claims 77 Preliminary Injunction Against 77 Files Patent Infringement Lawsuit 77 Patent Infringement Claim 76 Infringement Case 76 Settles Litigation 76 Receives Favorable Ruling 76 Favorable Ruling 76 Wins Summary Judgment 75 Infringement Suit 75 Patent Infringement Suit Against 75 Settle Patent Litigation 75 Antitrust Case 74 Settles Patent Infringement Lawsuit 74 Gets Favorable 74 Settle Patent 74 Files Patent 74 Patent Infringement Lawsuits 74 Antitrust Lawsuit 74 Infringed 74 Settles Patent Litigation 74 Receives Favorable 74 Patent Suits 74 Announces Favorable Ruling 73 Announces Dismissal 73 Settle Litigation 73 Patent Litigation 72 Patent Disputes 72 Initiates Patent Infringement 72 Announce Settlement 72 Infringes 72 Settle Patent Dispute 72 Announces Favorable 72 Files Lawsuits 71 Arthritis Drug 71 Settles Patent Dispute 71 Files Patent Suit 71 Nasdaq Delisting 71 Injunction Against 71 Patent Validity 71 Patent Upheld 71 Settles Charges 71 Licensing Pact 71 Antitrust Suit 71 Files Antitrust Suit 71 Generic Version 70 Antitrust Probe 70 Shareholder Lawsuit 70 Patent Reexamination 70 False Advertising 70 Patent Spat 70 Patents Upheld 70 Completes Tender Offer 70 Antitrust Complaint 70 Confirms Validity 70 Vigorously Defend 70 Announce License Agreement 70 Jury Verdict 70 Begins Shipment 70 Files Antitrust Lawsuit 70 Receives Subpoena 69 Pending Litigation 69 Purported Class 69 Wins Dismissal 69 Trademark Infringement Lawsuit 69 Trademark Dispute 69 Plans Job Cuts 69 Sign Licensing Agreement 69 Derivative Lawsuit 69 Reaffirms Outlook 69 Q4 Profit Plunges 68 Million Verdict 68 Q1 Loss Widens 68 Shareholder Claims 68 Announces FDA Clearance 68 Unsolicited Proposal From 68 Acacia Subsidiary 68 Patent Issued 68 Files IND 68 Court Dismisses Lawsuit 68 Trademark Lawsuit 68 Generic Versions 68 3Q Profit Plunges 68 Countersuit 68 Sign License Agreement 68 Dismiss Lawsuit 68 Posts 1Q Profit 68 Announces Tentative Approval 68 Lowers Guidance 68 Legal Dispute 68 Permanent Injunction Against 68 Biotech Firm 68 Shareholder Suits 68 Shareholder Suit 68 Licenses Patents 68 Vioxx Suits 67 Copyright Infringement Case 67 Settles Patent Suit 67 4Q Profit Soars 67 Board Unanimously Rejects 67 Ups Guidance 67 FDA Clears 67 Posts 4Q Profit 67 Settles Claim 67 Receives Approvable Letter 67 Narrows 4Q Loss 67 Licensing Deal 67 Milestone Payment 67 Announce Licensing Agreement 67 Denies Motion 67 Pomerantz Law Firm 67 Q2 Adj 67 Plans Buyback 67 Seeks Injunction 67 Receives Milestone Payment 67 Device Maker 67 Receives Patent 67 Unsolicited Tender Offer 67 Develop Novel 67 Antitrust Settlement 67 #cv# [003] 67 Dismiss Case 67 Pending Acquisition 67 Trademark Infringement 67 Posts Wider Loss 67 Reconfirms 67 Attorneys Fees 67 Board Authorizes 67 Commercializes 67 Inequitable Conduct 67 Restate Financials 67 Receives Notification 67 Achieves Significant 67 Posts 2Q Profit 67 Signs License Agreement 67 Malpractice Suit 67 Nasdaq Delisting Notice 66 Announce Early Termination 66 Whistleblower Suit 66 Cholesterol Drug 66 Action Suit 66 Q2 Profit Plunges 66 Announce Expiration 66 Files Motion 66 Extends Tender Offer 66 Permanent Injunction 66 No. #-# Fed. 66 Q1 Profit Soars 66 Court Invalidates 66 Shares Soar 66 4Q Profit Surges 66 Boosts Outlook 66 Terminate Merger Agreement 66 Drug Maker 66 Gets Favorable Ruling 66 Q3 Profit Jumps 66 Ups Bid 66 Q2 Profit Soars 66 Shares Plummet 66 Completes Patient Enrollment 66 Non Infringement 66 Trims Outlook 66 Q4 Loss Narrows 66 Q2 Profit Surges 66 Backdating Case 66 Issued Patent 66 Blood Thinner 66 Extends Collaboration 66 Shareholder Lawsuit Against 66 Discontinues 66 FDA Panel Recommends 66 Lung Cancer Drug 66 Develop Next Generation 66 Successfully Defends 66 Suit Vs 66 Lawsuit Brought 66 Drug Fails 66 Generic Version Of 66 Antitrust Ruling 66 Epilepsy Drug 66 Reverses Loss 66 Submits NDA 66 1Q Loss Widens 66 Wider Loss 66 Strengthens Position 66 Patent Invalid 66 Q3 Loss Narrows 66 Osteoporosis Drug 66 Announces Licensing Agreement 66 Q1 Loss Narrows 66 Earnings Cheat Sheet 66 Patent Infringement Complaint 66 Obtains Exclusive Rights 65 Teva Provides Update 65 Files Countersuit Against 65 Licenses Novel 65 Q4 Profit Surges 65 Signs Licensing Agreement 65 Successfully Completes Tender Offer 65 Settles Dispute 65 Gets FDA Clearance 65 Q3 Adj 65 Submits Biologics License Application 65 License Pact 65 Buyout Bid 65 Q2 Loss Narrows 65 3Q Loss Widens 65 Takeover Speculation 65 HSR Waiting Period 65 Receives Orphan Drug Designation 65 Trims Loss 65 Gout Drug 65 Q4 Profit Drops 65 1Q Profit Down 65 Trademark Suit 65 Settle Lawsuits 65 Backs FY# Outlook 65 Q1 Adj 65 Earns Milestone Payment 65 Receives FDA Clearance 65 Gets Subpoena 65 Markman Hearing 65 Analyst Upgrade 65 Q4 Profit Soars 65 Reaches Settlement Agreement 65 Announces License Agreement 65 Receives Tentative Approval 65 Investigates Claims 65 Explores Strategic Alternatives 65 #cv# [001] 65 Q3 Loss Widens 65 Files Patent Application 65 Announces Immediate Availability 65 Q2 Loss Widens 65 2Q Profit Down 65 Files Lawsuit 65 Posts 2Q Loss 65 Patent Covering 65 Rehear 65 Taro Receives 65 Files Amended Complaint 65 4Q Profit Down 65 Expand Collaboration 65 Profit Dips 65 Stock Soars 65 Terminate Agreement 65 Receives CE Marking 65 Inks License 65 Punitive Damages 65 Q2 Profit Plummets 65 Raises Guidance 65 Acquire Assets 65 Posts 2Q 65 Beats Views 65 Lawsuit Involving 65 Lowers Forecast 65 Stock Plunges 65 Teva Pharma 65 CFO Resigns 65 BioSante Pharmaceuticals Announces 65 Settle Shareholder 65 Explore Strategic Alternatives 65 4Q Profit Slips 65 Hostile Bid 65 Schizophrenia Drug 65 Guides Inline 65 Court Dismisses 65 Amend Merger Agreement 65 Beats Expectations 65 Posts 4Q Loss 65 Q3 Profit Soars 65 Settle Antitrust 65 Achieves Milestone 65 Files Suit 65 Initiates Enrollment 65 Launches Generic Version 65 Misses Expectations 65 Narrows Loss 64 Awarded Patent 64 Action Suit Against 64 Injunctive Relief 64 Receives Complete Response 64 Sex Discrimination Case 64 Cross Licensing Agreement 64 Announce Collaboration Agreement 64 Restates Earnings 64 Settle Dispute 64 Wins Approval 64 4Q Loss Widens 64 Declaratory Judgment 64 4Q Profit Jumps 64 Shareholder Lawsuits 64 Profit Exceeds Estimates 64 Inhaled Insulin 64 Patient Enrollment 64 Investigating Shareholder 64 1Q Profit Slips 64 Exploring Strategic Alternatives 64 Announces Definitive Agreement 64 2Q Loss Widens 64 Shares Surge 64 Q1 Profit Jumps 64 #.#B Bid 64 Receives Positive 64 Files Voluntary 64 Q3 Profit Drops 64 Q2 Profit Drops 64 Q4 Loss Widens 64 Fourth Quarter Profit Drops 64 Rheumatoid Arthritis Drug 64 Boosts Buyback 64 Profit Beats Estimates 64 Submits Application 64 Settles Lawsuits 64 Kickback Case 64 Lifts FY# Outlook 64 Mylan Receives Approval 64 Drug Coated Stent 64 Shares Climb 64 Reduces Debt 64 2Q Profit Up 64 Restate Results 64 Obtains Exclusive License 64 Jury Verdict Against 64 Action Suit Filed 64 Milestone Payments 64 Broadens Scope 64 Rehearing 64 Amends Agreement 64 Expects 1Q 64 Judge Tosses Out 64 Antitrust Clearance 64 Action Lawsuits 64 Reaffirms FY# Outlook 64 Losses Narrow 64 Court Vacates 64 Submits Supplemental 64 Claim Against 64 Complaint Filed 64 1Q Profit Falls 64 FDA Approvals 64 Migraine Drug 64 3Q Profit Falls 64 Initiates Phase II 64 Announces Early Termination 64 Reach Settlement Agreement 64 Seeks Damages 64 Raises Outlook 64 Share Buyback 64 3Q Profit Drops 64 4Q Profit Drops 64 Receives Clearance 64 Completes Enrollment 64 Antitrust Lawsuit Against 64 Suit Filed 64 Narrows Guidance 64 Slashes Guidance 64 Shareholder Investigation 64 3Q Profit Down 64 Lowers Outlook 64 Q3 Profit Surges 64 Found Liable 64 Meets Primary Endpoint 64 Voluntarily Withdraws 64 Infringe 64 Weight Loss Drug 64 Losses Widen 64 3Q Profit Up 64 Withdraws Application 63 Withdraws Proposal 63 Q1 Profit Plunges 63 4Q Profit Falls 63 Posts 1Q 63 1Q Loss Narrows 63 Terminates Merger Agreement 63 Posts Wider 4Q Loss 63 Backs FY# View 63 3Q Profit Rises 63 Receives Unsolicited 63 Whistleblower Lawsuit 63 Q1 Profit Drops 63 Million Milestone Payment 63 Commenced Against 63 Initiates Phase III 63 Hikes Dividend 63 Raises Bid 63 Expand Relationship 63 Court Nixes 63 Regulatory Clearance 63 Summary Judgment Order 63 Submits IND 63 Expands Portfolio 63 Distribution Pact 63 Upholds Ruling 63 Settles Suit 63 Lifts Dividend 63 Psoriasis Drug 63 Extend Partnership 63 LLP Investigates 63 Clears Path 63 Court Reverses 63 Cigarette Maker 63 Proxy Fight 63 Unsolicited Proposal 63 Confirms Receipt 63 Stockholders Reject 63 Purchases Moore Microprocessor 63 Terminates Agreement 63 Posts Strong 63 Court Upholds Ruling 63 Demonstrates Significant 63 Files Petition 63 Posts 3Q Profit 63 Tops Estimates 63 Buyback Plan 63 Boosts Dividend 63 Introduces Enhanced 63 Revises FY# Outlook 63 First Patient Treated 63 Verdict Upheld 63 Unveils Newest 63 Goldfarb Branham Law Firm 63 Cholesterol Lowering Drug 63 Has Spiked 63 Finalize Agreement 63 Expanded Indication 63 Q4 Adj 63 Lowers Price 63 Share Buybacks 63 Settles Fraud 63 NDA Submission 63 Misled Investors 63 Resolves Dispute 63 Strengthens Balance Sheet 63 Cuts Costs 63 Profit Soars 63 NASDAQ Delisting Notice 63 Analyst Downgrade 63 Buyout Talks 63 Reaffirms FY# Guidance 63 Q3 Profit Plunges 63 FDA Okays 63 Suit Against 63 Obtains Approval 63 FDA Accepts 63 Updates Guidance 63 Provides Update Regarding 63 Net Loss Narrows 63 3Q Profit Jumps 63 Announces Stockholder Approval 63 Expands Scope 63 Jumps Higher 63 Restructures Operations 63 Completes Purchase Of 63 1Q Profit Jumps 63 Price Fixing 63 Stockholders Approve Merger 63 1Q Profit Rises 63 Meets Estimates 63 KB Home Swings 63 Obtains License 63 Sign Definitive Agreement 63 1Q Profit Tumbles 63 1Q Profit Up 63 False Marking 63 Exec Sees 63 Loss Shrinks 63 Suit Settled 63 Q4 Profit Decreases 63 Boosts Quarterly Dividend 63 Earnings Scorecard 63 Appeals Court Upholds 63 Files Provisional 62 Lawsuit Alleging 62 Complaint Against 62 Complies With 62 Court Reverses Ruling 62 Settles Dispute With 62 Exclusive License 62 Insulin Pen 62 Begins Shipping 62 Suit Alleges 62 Testosterone Gel 62 Patent Infringements 62 Posts 3Q 62 Files Trademark 62 Update# 62 Decision Upholding 62 Planned Acquisition 62 Revises Guidance 62 Wider Than Expected 62 Above Estimates 62 Nanophase Announces 62 Sweetens Bid 62 Spears Conservatorship 62 2Q Profit Slides 62 Settle Dispute Over 62 Posts Smaller 62 Secures Patent 62 CHMP Opinion 62 Reports 4Q Loss 62 1Q Profit 62 Court Overturns 62 Recall Issued 62 Stock Buyback 62 Previously Disclosed 62 Q1 Profit Dips 62 IG HCR ;) CO 62 Generic Protonix 62 Citi Downgrades 62 Discrimination Case 62 Rehearing En Banc 62 Revenues Decline 62 Has Filed 62 Exceeds Estimates 62 Estimate Analyst Blog 62 Stock Tumbles 62 Slashes Price 62 Q2 Profit Declines 62 Announce Initiation 62 Blood Pressure Drug 62 Restructures Debt 62 Stays Neutral 62 Cross License Agreement 62 Not Liable 62 Unveils Expanded 62 Announces Discontinuation 62 Antitrust Violations 62 4Q Profit Up 62 Buyout Rumors 62 Appeals Upholds 62 Fraud Suit 62 Diet Pill 62 Immunomedics Announces 62 Increases Share Repurchase 62 Settlement Reached 62 Nearly Triples 62 Posts Loss 62 Results Disappoint 62 Wrongful Death Lawsuit Filed 62 OKs Buyback 62 Unveil Next Generation 62 2Q Profit Soars 62 Court Throws Out 62 Antitrust Approval 62 Q3 Profit Slips 62 Share Repurchases 62 4Q Profit Slides 62 Delivers Next Generation 62 Reaches Definitive Agreement 62 Reveals Positive 62 Enrolls First 62 4Q Profit Rises 62 Posts Narrower Loss 62 Delays Filing 62 Collaborates With 62 Protects Customers 62 Favorable Decision 62 Lawsuit Dismissed 62 3Q Profit Dips 62 Regains Nasdaq 62 Confirms Commitment 62 Signs Merger Agreement 62 Awarded Patents 62 Provides Guidance 62 Can Proceed 62 Drug Shows Promise 62 Announce Licensing 62 Revises FY# Guidance 62 Initiates Clinical Trial 62 Q1 Profit Slips 62 Receives Commitment 62 Q1 Profit Declines 62 Posts Profit 62 Anemia Drug 62 Files Complaint 62 Q4 Profit Declines 62 OxyContin Maker 62 Clinical Trial Results 62 Patents Covering 62 Reaches Tentative Settlement 62 Successfully Concludes 62 Acquire Privately Held 62 Gets Clearance 62 Streamlines Operations 62 Ruling Upheld 62 Initiates Clinical Trials 62 2Q Profit Falls 62 Finalizes Acquisition 62 Lupus Drug 62 Begins Tender Offer 61 2Q Profit 61 Judge Overturns 61 Court Dismisses Suit 61 Claim Filed 61 Action Lawsuit 61 Drug Candidate 61 Enters Into Exclusive 61 Misses Views 61 Raises Dividend 61 Authorizes Additional 61 Extend Collaboration 61 Commences Tender Offer 61 2Q Profit Surges 61 VP Exercises Options 61 Q2 Profit Rises 61 Shares Tumble 61 Provides Status 61 Initiates Voluntary Recall 61 Regains Full 61 For Undisclosed Terms 61 Device Makers 61 2Q Profits 61 Billion Buyback 61 DVD Copying 61 Slashes Outlook 61 Initiates Clinical 61 Age Bias 61 Below Consensus 61 Stockholders Approve Acquisition 61 Unveils Groundbreaking 61 reaffirms FY# outlook 61 Settle Fraud 61 Settles Lawsuit 61 Announces Definitive Agreements 61 Q4 Profit Jumps 61 Unveils Revolutionary 61 Accelerate Commercialization 61 Beats Consensus 61 Announcement acc 61 Sees Profit 61 4Q Profit Doubles 61 Halts Production 61 Significantly Reduces 61 Doubles Capacity 61 Files Shelf Registration Statement 61 Successfully Integrates 61 Receives NASDAQ 61 Q4 Profit Slips 61 Chip Makers 61 Court Overturns Ruling 61 Profit Sinks 61 2Q Profit Doubles 61 Provides Preliminary 61 Reminds Shareholders 61 Acquire Controlling Interest 61 Reach Settlement 61 Appeals Affirms 61 Makes Unsolicited Bid 61 Lowers FY# Outlook 61 Debuts Next Generation 61 Presents Positive 61 Study Showed 61 Regains Compliance 61 Announce Receipt 61 Court Hears Arguments 61 Contract Dispute 61 Demonstrates Commitment 61 Above Consensus 61 Significantly Increases 61 Announces Initiation 61 STERIS Corporation Announces 61 Tops Estimate 61 Eliminates Need 61 Receives Notice From 61 Stock Buyback Plan 61 Introduces Next Generation 61 IND Application 61 Inks Licensing Deal 61 Subsidiary Wins 61 Profits Climb 61 Wins Injunction 61 Approve Merger 61 Enters Strategic 61 Files Definitive Proxy 61 Issues Recall 61 Regains Compliance With 61 1Q Profit Drops 61 NASDAQ Delisting 61 LLP Investigating 61 Profit Doubles 61 Key Milestones 61 Successfully Completes Acquisition 61 Misses Estimate 61 Q1 Profit Decreases 61 Misses Estimates 61 Generic Lovenox 61 Neutral Analyst Blog 61 Acacia Subsidiary Enters 61 Acquire Controlling Stake 61 Discrimination Suit 61 Canaccord Genuity Reiterates Buy 61 Lawsuit Filed 61 Presents Preclinical Data 61 Damages Claim 61 Settle Suit 61 Anemia Drugs 61 Trial Halted 61 Lifts FY# Guidance 61 Acne Medication 61 Exec Says 61 Achieves Positive 61 3Q Loss 61 Appeal Ruling 61 Prostate Cancer Vaccine 61 Starts Shipping 61 Successfully Closes 61 Copyright Infringement 61 Loss Widens 61 Q3 Profit Declines 61 Spins Off 61 Extends Expiration Date 61 Named Exclusive Distributor 61 4Q Loss 61 Resubmit 61 Update8 61 Initiates Dosing 61 Earnings Postmortem 61 Acquires Exclusive 61 Quadruples 61 Patients Enrolled 61 1Q Loss 61 Waiting Period 61 Receives Approvals 61 2Q Loss Narrows 61 Case Involving 61 Resolves Litigation 61 Reports Receipt 61 Patent Filings 61 Forecast Quick Facts 61 Announces Successful Completion 61 Granted Early Termination 61 Case Nos. #-# 61 Extends Offer 61 Fentanyl Patch 61 Completes Merger With 61 4Q Profit 61 Tax Evasion Case 61 Announces Proposed Settlement 61 Terminates Contract 61 Restates Results 61 3Q Profit 61 Sexual Harassment Case 61 Share Buyback Program 61 Confirms Guidance 61 Options Backdating 61 Lawsuit Against 61 Narrower Loss 61 Heartburn Drugs 61 Initiate Phase III 61 #.#B Vioxx 61 Markman Ruling 61 Stock Plummets 61 Resolve Dispute 61 Asset Swap 61 Seeks Dismissal Of 61 Defamation Lawsuit 61 Judge Nixes 61 Receives Tentative FDA 60 Arbitration Claim 60 Grossly Inadequate 60 Shows Promising 60 Shareholders Approve Merger Agreement 60 Files Lawsuit Against 60 Beats Estimates 60 FTC Clears 60 Faces Delisting 60 Subsidiary Enters 60 2Q Profit Dips 60 Antitrust Suit Against 60 Significantly Improves 60 Files Claim 60 Formalizes 60 Confirmatory Phase 60 PDUFA Date 60 Denies Bid 60 Delivers Comprehensive 60 Enters Into Licensing Agreement 60 Halts Sale 60 Flamel Technologies Announces 60 Earnings Decline 60 Jointly Develop 60 Accounting Errors 60 Posts 3Q Loss 60 2Q Profit Rises 60 Sell Itself 60 Lawsuits Filed 60 Justices Weigh 60 Regains NASDAQ 60 1Q Profit Soars 60 File Sharing Case 60 Reaches Settlement 60 Profits Rise 60 Receives FDA Approvable 60 Restate Financial 60 Improves Survival 60 Strengthens Its 60 Multimillion Dollar 60 Impax Labs 60 Has Received 60 Increases Buyback 60 TriCo Bancshares Announces 60 Gets Approval 60 Announce Definitive Agreement 60 Buyout Offer 60 Receives SFDA Approval 60 Unveils Next Generation 60 Investigational Compound 60 FDA Warns 60 Study Demonstrates 60 Patents Issued 60 Evaluate Strategic Alternatives 60 Copyright Infringement Lawsuit 60 Court Reinstates 60 Collaborators Publish 60 4th Qtr Profit Rises 60 Commercially Available 60 Guides Q2 60 Receive Milestone Payment 60 Universal Shelf Registration 60 Controlling Stake 60 Reveals Receipt 60 Dividend Hike 60 Receives Orphan Drug 60 Below Estimates 60 Boosts Share Buyback 60 Complete Merger 60 Deliver Powerful 60 Appeal Upholds 60 Avian Flu Vaccine 60 Profit Slides 60 Directors Authorizes 60 NASDAQ Listing Requirements 60 Milestone Payment From 60 Finalizes Purchase 60 Profit Fell 60 Announces Divestiture 60 Expects 4Q 60 Sees 3Q 60 Shareholder Derivative 60 Completes Divestiture 60 Gets Tentative 60 Beat Estimates 60 * vwd PRN 60 CFO Exercises Options 60 Low Dose 60 Enemy Combatant Case 60 Backs FY# Guidance 60 Obtains FDA 60 ONN.tv Report 60 Final Approval 60 Judge Tosses 60 Silicone Breast Implants 60 Upholds 60 More Than Doubled 60 Withdraws Offer 60 H.B. Fuller 60 Partial Settlement 60 Movers Roundup 60 Case Thrown Out 60 Fee Dispute 60 Q3 Profit Rises 60 Therapeutic Competitors Report 60 COO Exercises Options 60 Loss Narrows 60 Cuts Forecast 60 CEO Exercises Options 60 Strengthens Commitment 60 Ruling Favors 60 Expands Internationally 60 Judge Clears Way 60 Approves Merger 60 Settle Suits 60 Seeks Approval 60 Civil Penalty 60 Wrongful Death Case 60 Reports Significantly Improved 60 Broadens Its 60 Arbitration Proceeding 60 #M Buyback [002] 60 Sees Wider 60 Completes Reorganization 60 Subsidiary Receives 60 Posts Wider Than Expected 60 Nasdaq Listing Requirements 60 Appeal Denied 60 Secures Financing 60 Novel Antibiotic 60 Countersues 60 non infringement invalidity 60 Completes Transaction 60 Receives Fast Track 60 Manufacturer Selects 60 Revises Third Quarter 60 Develop Innovative 60 NewsBite Downgrade Puts Pressure 60 Settle Lawsuit 60 Review Strategic Alternatives 60 Signs Purchase Agreement 60 Buys Majority Stake 60 TiVo Posts Narrower 60 Q3 Profit Decreases 60 Defamation Case 60 Sinorgchem 60 Completes Transition 60 Considers Sale 60 Patent Troll 60 Further Strengthens 60 Seek Damages 60 4Q Profit Tumbles 60 Flagship Product 60 alleging patent infringement 60 Summary Judgment Motion 60 Lawsuit Alleges 60 Delivers Solid 60 Extend Relationship 60 Enters Agreement 60 Q4 Profit Rises 60 Asbestos Claims 60 Receives Anticipated 60 Taglich Brothers Initiates Coverage 59 b#x# http:/#.#.#.#/fls.geo/PH #x# #.hyahrtzeit 59 Announces Effective Date 59 Issues Statement Regarding 59 Asthma Treatment 59 Twersky LLP Announces 59 Hires Lobbyist 59 Domain Name Dispute 59 Lowers 3Q 59 Rejects Request 59 Cholesterol Drugs 59 Stem Cell Patents 59 Settle False Claims 59 Closes Acquisition Of 59 Q1 Profit Rises 59 Submits Response 59 Dismiss Charges 59 Significantly Enhances 59 Positive Opinion 59 Bullish Speculation 59 Investigation Relating 59 Profit Drops 59 Raises Quarterly Dividend 59 Restate Earnings 59 Hold Fourth Quarter 59 Contaminated Heparin 59 Directors Authorizes Additional 59 Delivers Enhanced 59 Inc. Endures Analyst 59 Completes Sale Of 59 Approaching Resistance 59 Sets Precedent 59 Enters Into License Agreement 59 Revenue Climbs 59 Provides Shareholder 59 4Q Loss Narrows 59 Momentum Continues 59 Extends Leadership 59 Amends Credit 59 Nears Settlement 59 Posts Wider 2Q 59 Settle Claims 59 Announce Collaboration 59 Jointly Developed 59 FY# Loss Widens 59 Authorized Generic 59 Cervical Cancer Vaccine 59 Sign Definitive Merger 59 Phase III Trial 59 Unveils Innovative 59 Renews Agreement 59 Study Validates 59 Mini Tender Offer 59 Bearish Speculation 59 Seek Shareholder Approval 59 3Q Earnings 59 Jointly Offer 59 Files Suit Against 59 Extends Maturity 59 Supplemental Biologics License Application 59 FY# Loss Narrows 59 FDA Approves Generic 59 Panasonic ReadSoft

Back to home page